Wu Yu, Wang Huan, Wu Qi-Yan, Liang Xiao-Lei, Wang Jing
Department of obstetrics and gynecology, The First Hospital of Lanzhou University, Key Laboratory of Gynecologic Oncology Gansu Province, Lanzhou, 730000, Gansu, People's Republic of China.
The First Clinical Medical College of Lanzhou University, Lanzhou, 730000, Gansu, People's Republic of China.
Arch Gynecol Obstet. 2020 Mar;301(3):643-653. doi: 10.1007/s00404-020-05467-9. Epub 2020 Mar 2.
Clinical studies and trials have shown that oxytocin can effectively reduce postpartum bleeding, whether by intramuscular (IM) injection or intravenous (IV) injection. These two methods are widely used in the prevention and treatment for the third stage of childbirth. However, it is unclear whether the subtle differences between the mode of these routes have any effect on maternal outcomes.
To systematically evaluate the efficacy and safety of oxytocin administered intramuscularly or intravenously for prophylactic management of the third stage of labor after vaginal birth.
Computerized retrieval of PubMed, the Cochrane Library, Web of Science, Embase, and ClinicalTrials.gov was conducted to collect randomized controlled trials (RCT) on the effects of IM and IV oxytocin on the third stage of labor. After independent literature screening, data extraction and evaluation of the bias risk of included studies by two evaluators, RevMan 5.3 software was used for a meta-analysis.
Six studies with 7734 women were included in this study. Meta-analysis results showed that: the severe postpartum hemorrhage (PPH) rate [risk ratio (RR) 1.54, 95% confidence interval (95% CI) 1.08-2.20, P = 0.02], PPH rate (RR 1.31, 95% CI 1.11-1.55, P = 0.001), incidence of blood transfusion (RR 2.30, 95% CI 1.35-3.93, P = 0.002) and the need of manual removal of placenta (RR 1.44, 95% CI 1.05-1.96, P = 0.02) for IM group were higher than IV group, but there were no significant differences in the use of additional uterotonics (P = 0.31) and the incidence of serious maternal morbidity and adverse effects between two groups. None of the included studies reported maternal death.
For clinical practice, intravenous injection oxytocin 10 IU may be a good, safe option in the management of the third stage of labor. Medical conditions, available resources, adverse effects, and women' s preferences should also be considered. If an IV line is already in place at delivery, IV administration may be preferable to IM injection.
临床研究和试验表明,催产素无论是通过肌肉注射还是静脉注射,都能有效减少产后出血。这两种方法广泛用于分娩第三阶段的预防和治疗。然而,这些给药途径方式之间的细微差异是否会对产妇结局产生影响尚不清楚。
系统评价肌肉注射或静脉注射催产素预防性处理阴道分娩后第三产程的有效性和安全性。
通过计算机检索PubMed、Cochrane图书馆、Web of Science、Embase和ClinicalTrials.gov,收集关于肌肉注射和静脉注射催产素对第三产程影响的随机对照试验(RCT)。经两名评价者独立进行文献筛选、数据提取及纳入研究的偏倚风险评估后,采用RevMan 5.3软件进行荟萃分析。
本研究纳入6项研究,共7734名女性。荟萃分析结果显示:肌肉注射组的严重产后出血(PPH)率[风险比(RR)1.54,95%置信区间(95%CI)1.08 - 2.20,P = 0.02]、PPH率(RR 1.31,95%CI 1.11 - 1.55,P = 0.001)、输血发生率(RR 2.30,95%CI 1.35 - 3.93,P = 0.002)及人工剥离胎盘的需求(RR 1.44,95%CI 1.05 - 1.96,P = 0.02)均高于静脉注射组,但两组在使用额外宫缩剂方面无显著差异(P = 0.31),且严重孕产妇发病率和不良反应发生率也无显著差异。纳入研究均未报告孕产妇死亡。
对于临床实践,静脉注射10 IU催产素可能是处理第三产程的一个良好、安全的选择。同时也应考虑产妇的病情、可用资源、不良反应及产妇的偏好。如果分娩时已有静脉通路,静脉给药可能优于肌肉注射。